Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?

ABSTRACT: Since its approval in 2018 by the US Food and Drug Administration, peptide receptor radionuclide therapy (PRRT) has become a mainstay in the treatment of neuroendocrine tumors. Lutetium-177-DOTATATE, the only approved agent, is indicated for the treatment of gastroenteropancreatic-neuroendocrine tumors. Although patient selection appears straightforward with somatostatin receptor-positron emission tomography, there is considerable complexity when deciding which patients to treat and when to start PRRT. Herein, we review the many factors that affect patient selection, focusing on the optimal patients to treat. Although significant effort has been expended to determine which patients benefit the most from PRRT, a validated predictive biomarker remains elusive. Although PRRT has been used for

SUBMITTER: Hope TA 

PROVIDER: S-EPMC9390818 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature